Companion diagnostic sales will reach $10.52 billion worldwide in 2020, new market analysis reveals

03 September 2018
Pharma

A report by visiongain, published in August 2016, predicts overall global sales of companion diagnostic products will reach $10.52 billion in 2020. That sales expansion will continue strongly through to 2026, helped by the entrance of new industry players, advances in diagnostic technology and developments in personalised medicine.

That revenue forecast and other analyses appear in Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016 – Market Analysis and Company Profiles Including Abbott Laboratories, Myriad Genetics, Roche, Qiagen, Agilent Technologies, Siemens, Johnson & Johnson and Other Companies in the US, Europe, Israel, India, Canada and South Korea, Exploring those Diagnostic Products for Personalised Medicine and Partnerships with Pharmaceutical Developers.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand commercial prospects of industries and markets in healthcare and other fields.

Companion diagnostics are in vitro diagnostic tests providing information for the safe and effective use of corresponding drugs. The use of those tests helps physicians evaluate the efficacy and safety of a specific pharmaceutical in a group or sub-group of patients. Certain drugs have been known to be effective only in sub-segments of the patient population. The use of companion diagnostics allows for therapies to be administered only to people who are most likely to benefit from a particular treatment, aiding therapeutic efficiency and cost effectiveness.

Visiongain's new survey analyses 17 leading companion diagnostic developers, manufacturers and marketers from the US, Europe, Asia-Pacific and Israel, including these companies:

• Abbott Laboratories
• Myriad Genetics
• Genomic Health
• Thermo Fisher Scientific
• Johnson & Johnson
• Roche
• Qiagen
• Siemens Healthcare.

That investigation discusses top companies, exploring their activities by:

• Analysing companion diagnostic product portfolios and technologies
• Investigating the status of commercial developments
• Assessing R&D and products’ applications
• Uncovering organisations’ strengths, weaknesses, activities, strategies and prospects
• Giving qualitative analyses and revenue forecasting of the companion diagnostics market, explaining opportunities and challenges from 2016.

Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostic tests and outsourced services.

Recent News

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever